In a groundbreaking shift for healthcare access, Hainan's Boao Lecheng International Medical Tourism Pilot Zone has reduced approval timelines for overseas medical products from years to an average of 1.6 days. This acceleration is transforming treatment options for rare disease patients across the Chinese mainland while reshaping Asia's medical innovation landscape.
As China's sole "medical special zone," Lecheng has introduced over 500 foreign-approved medicines and devices previously unavailable domestically. The zone's unique status within the Hainan Free Trade Port framework enables rapid approvals through streamlined regulatory processes, attracting partnerships with 180+ global pharmaceutical firms across 20 countries and regions.
Medical professionals highlight the human impact: "For conditions like spinal muscular atrophy or advanced cancers, this policy literally saves lives," said Dr. Li Wei, a Beijing-based oncologist. The development also positions Hainan as a strategic hub for Asia's US$1.3 trillion healthcare market, with cross-border clinical trials increasing 78% this year.
